Explore plain language summaries that break down complex Niemann-Pick disease research, clinical trials, and treatment developments into clear, accessible information for patients, families, and caregivers.
Scientific research can be complex, but understanding it shouldn’t have to be.
Plain language summaries explain scientific studies and research findings in clear, everyday language. They break down complicated medical terms and scientific concepts, making important information easier to understand for individuals and families affected by Niemann-Pick disease.
These summaries help our community stay informed about the latest research, better understand scientific discoveries, and feel more confident navigating the evolving landscape of Niemann-Pick disease research and treatments.
We believe every patient, family, and caregiver should have access to clear, understandable information about Niemann-Pick disease.
Plain language summaries help make complex research more accessible, and provide families with the knowledge they need to make informed decisions about care and treatment.
Heather Teal
Executive Director, NNPDF
An overview of ongoing clinical trials in Niemann-Pick disease, including NAVIGATE (nizubaglustat) and TransportNPC (Trappsol Cyclo).
Please note: The TransportNPC (Trappsol Cyclo) trial has closed recruitment.
A summary of study results evaluating the efficacy and safety of arimoclomol in individuals with NPC.
A summary of findings from a 12-month, double-blind randomized trial of arimoclomol.
A summary of research on the use of intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol Cyclo) in NPC.
A summary of long-term administration of intravenous Trappsol Cyclo in NPC.
A summary of the efficacy and safety of efavirenz in adults with NPC and cognitive impairment.
A summary of a randomized controlled study of miglustat in NPC.
A summary of long-term clinical trial data in adult and juvenile patients with NPC.
A summary of the final NPC Registry report on continuous miglustat therapy.
A summary of study results evaluating the efficacy and safety of N-acetyl-L-leucine in individuals with NPC.
A summary of research on the neuroprotective effect of N-acetyl-L-leucine in adult and pediatric patients with NPC.
A summary of a clinical trial of N-acetyl-L-leucine in Niemann-Pick disease type C.
A summary of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of nizubaglustat in healthy adults.
A summary of one-year results from a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with ASMD.
Become an NNPDF member for the latest research updates, event invitations, and a direct line to the community.
